# Randomised EValuation of Therapies for microvAscuLar Injury in STEACS

Study · id `cardio:ct-nct06935383` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06935383](<https://clinicaltrials.gov/study/NCT06935383>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06935383

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

## Technical summary

Registry record NCT06935383. Randomized; single masking; primary purpose other. Start 2025-09 (anticipated); primary completion 2027-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose other
- Phase: Phase 2
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT06935383, source copy `cardio:ctgov-nct06935383-2025-04-20`, retrieved 2026-10-26)
- Planned start: 2025-09 (anticipated) (ClinicalTrials.gov record NCT06935383, source copy `cardio:ctgov-nct06935383-2025-04-20`, retrieved 2026-10-26)
- Primary completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06935383, source copy `cardio:ctgov-nct06935383-2025-04-20`, retrieved 2026-10-26)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT06935383, source copy `cardio:ctgov-nct06935383-2025-04-20`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06935383-2025-04-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomised EValuation of Therapies for microvAscuLar Injury in STEACS
- Acronym: REVITALISE
- Condition: STEMI (ST Elevation MI)
- Intervention (Device): Therapeutic sequence
- Intervention (Device): Diagnostic sequence
- Lead sponsor: CorFlow Therapeutics AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)

## Provenance

Content hash: f345af8841ad6e867ebaba8b607f1de73a4653717c4be834ee866fe7c50d2d61
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
